The Institute of Medicine this week announced the names of 65 new members and five foreign associates at its 38th annual meeting. Election to the IOM recognizes individuals who have demonstrated outstanding professional achievement and commitment to service in the field of health and medicine.
Among the newly elected members are Jeffrey Gordon, Robert J. Glaser distinguished university professor and the director of the Center for Genome Sciences at Washington University School of Medicine - St. Louis; and Raju Kucherlapati, Paul C. Cabot professor of genetics at Harvard Medical School and the scientific director of Harvard Partners Center for Genetics and Genomics.
The newly elected members raise IOM's total active membership to 1,576 and the number of foreign associates to 89. With another 71 members holding emeritus status, IOM's total membership is now 1,736.
TheraGenetics this week announced the appointment of its new scientific advisory board, which will provide strategic guidance to the company in its development of pharmacogenetic tests for the treatment of critical CNS disorders.
The four inaugural members of the SAB are: Shitij Kapur, vice dean and professor at the Institute of Psychiatry at King’s College in London, who will serve as chairman of the board; Peter Jones, professor and department head of psychiatry at the University of Cambridge; Anil Malhotra, director of psychiatry research at the Zucker Hillside Hospital of the North Shore-Long Island Jewish Health System and associate professor of psychiatry at Albert Einstein College of Medicine; and Pak Sham, chair professor and department head of psychiatry of the LKS Faculty of Medicine at the University of Hong Kong.
Pathwork Diagnostics has appointed Fletcher Payne to be chief financial officer and Mark McDonough to be VP of US sales. Fletcher Payne previously was VP and CFO at Plexxikon, and he formerly worked at Dynavax Technologies, Cell Genesys, Sun Microsystems, and IBM.
McDonough has been VP of US sales at US Labs, a division of Laboratory Corporation of America, and he was involved in sales management at Ventana Medical Systems.
Berkeley HeartLab has tapped Christopher Hall to serve as chief business officer, succeeding Frank Ruderman, the former CEO and chairman who is leaving the company now that it has been integrated into Celera, which purchased BHL a year ago. Ruderman will continue to consult for Celera during a transition period.
Hall has held several executive roles at BHL, and he has been chief clinical operations officer since 2005.
Signature Genomic Laboratories has named Roger Schultz to serve as laboratory director. Schultz formerly was associate director of cytogenetics of Veripath Laboratories at the University of Texas Southwestern, where he worked for 15 years on research focused on genome stability and DNA repair mechanisms.
SQI Diagnostics has appointed Thomas O’Connor to be senior VP of sales and marketing. O’Connor formerly was an executive in sales and business development at Luminex, Beckman Coulter, and Exagen Diagnostics.